# US 2005/0032785 A1 · Methods of inhibiting metastases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032785 A1
- Document ID: US20050032785A1
- Status: Published application
- Kind: A1
- Application number: 10/873,802
- Filed: 2004-06-21
- Published: 2005-02-10
- Earliest claimed: 2001-10-01
- Assignees: Rhode Island Hospital
- Inventors: Jack Wands; Rolf Carlson; Paul Maggio
- Web page: https://patentgrep.com/patent/US20050032785A1

## CPC

- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.

## Claims

### Claim 1

A method of inhibiting the development of metastases of a primary tumor to a tissue of a liver in an individual after excision of the primary tumor, comprising directly contacting said tissue with taurolidine.

### Claim 2 (depends on 1)

The method of claim 1, wherein said primary tumor is not a liver tumor.

### Claim 3 (depends on 1)

The method of claim 1, wherein said primary tumor is in an organ of the peritoneal cavity.

### Claim 4 (depends on 1)

The method of claim 1, wherein said individual is identified as being at risk of developing a metastatic liver tumor.

### Claim 5 (depends on 1)

The method of claim 1, wherein said individual is a mammal.

### Claim 6 (depends on 5)

The method of claim 5, wherein said mammal is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein said individual is identified as suffering from a colorectal tumor.

### Claim 8 (depends on 1)

The method of claim 1, wherein said individual is identified as suffering from a tumor selected from the group consisting of a lung tumor, breast tumor, kidney tumor, colon tumor, esophageal tumor, testicular tumor, pancreatic tumor, melanoma, and choriocarcinoma.

### Claim 9 (depends on 1)

The method of claim 1, wherein said taurolidine is administered to said liver is by perfusion in a direction of naturally-occurring blood flow.

### Claim 10 (depends on 1)

The method of claim 1, wherein said liver is perfused with said taurolidine in situ.

### Claim 11 (depends on 1)

The method of claim 1, wherein said taurolidine is administered to said liver by retrograde perfusion.

### Claim 12

(Cancelled)

### Claim 13 (depends on 9)

The method of claim 9, wherein said perfusion is carried out in conjunction with an abdominal surgery.

### Claim 14 (depends on 1)

The method of claim 1, wherein said Taurolidine is administered by in-dwelling catheter.

### Claim 15 (depends on 1)

The method of claim 1, wherein said Taurolidine is administered at a dose which increased caspase activity in a cell.

### Claim 16 (depends on 1)

The method of claim 1, wherein said Taurolidine is administered intravenously.

### Claim 17 (depends on 11)

The method of claim 11, wherein said perfusion is carried out in conjunction with an abdominal surgery.

### Claim 18

A method of inhibiting adherence of a tumor cell in metastases of a primary tumor to a tissue of a liver, comprising directly contacting said tissue with taurolidine.

### Claim 19

A method of decreasing serum concentration of a tumor-associated antigen, comprising directly contacting said tissue with taurolidine.

### Claim 20 (depends on 19)

The method of claim 19, wherein said tumor-associated antigen is carcinoembryonic antigen (CEA).

### Claim 21 (depends on 19)

The method of claim 19, wherein said tumor-associated antigen is prostate-specific antigen (PSA).

### Claim 22

A method of inhibiting the development of multicentric hepatocellular carcinoma in a tissue of a liver of an individual, comprising directly contacting said tissue with taurolidine.

### Claim 23 (depends on 22)

The method of claim 22, wherein said individual is a mammal.

### Claim 24 (depends on 23)

The method of claim 23, wherein said mammal is a human.

### Claim 25 (depends on 22)

The method of claim 22, wherein said taurolidine is administered to said liver by perfusion in a direction of naturally-occurring blood flow.

### Claim 26 (depends on 25)

The method of claim 25, wherein said perfusion is carried out in conjunction with an abdominal surgery.

### Claim 27 (depends on 22)

The method of claim 22, wherein said liver is perfused with said taurolidine in situ.

### Claim 28 (depends on 22)

The method of claim 22, wherein said taurolidine is administered to said liver by retrograde perfusion.

### Claim 29 (depends on 28)

The method of claim 28, wherein said perfusion is carried out in conjunction with an abdominal surgery.

### Claim 30 (depends on 22)

The method of claim 22, wherein said taurolidine is administered by in-dwelling catheter.

### Claim 31 (depends on 22)

The method of claim 22, wherein said taurolidine is administered at a dose which increased caspase activity in a cell.

### Claim 32 (depends on 22)

The method of claim 22, wherein said taurolidine is administered intravenously.

### Claim 33

A method of monitoring inhibition of the development of metastases of a primary tumor to a tissue of a liver in an individual, comprising directly contacting said tissue with taurolidine and monitoring the development of said metastases in said tissue.

### Claim 34 (depends on 33)

The method of claim 33, wherein the development of said metastases is monitored using a process selected from the group consisting of CT scan, ultrasound and liver biopsy.
